These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1387653)

  • 21. Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women.
    Carmina E; Stanczyk FZ; Matteri RK; Lobo RA
    Fertil Steril; 1991 May; 55(5):872-6. PubMed ID: 1827073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
    Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increase in plasma steroid glucuronide levels in men from infancy to adulthood.
    Brochu M; Belanger A
    J Clin Endocrinol Metab; 1987 Jun; 64(6):1283-7. PubMed ID: 2952667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of estrogen on adrenal androgen sensitivity and secretion in polycystic ovary syndrome.
    Ditkoff EC; Fruzzetti F; Chang L; Stancyzk FZ; Lobo RA
    J Clin Endocrinol Metab; 1995 Feb; 80(2):603-7. PubMed ID: 7852527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On the origin of the elevated 17-hydroxyprogesterone levels after adrenal stimulation in hyperandrogenism.
    Azziz R; Rafi A; Smith BR; Bradley EL; Zacur HA
    J Clin Endocrinol Metab; 1990 Feb; 70(2):431-6. PubMed ID: 2137133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovarian enlargement as a possible marker of androgen activity in polycystic ovary syndrome.
    Puzigaća Z; Prelević GM; Stretenović Z; Balint-Perić L
    Gynecol Endocrinol; 1991 Sep; 5(3):167-74. PubMed ID: 1837973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of 3alpha-androstanediol glucuronide in young women with polycystic ovary syndrome, idiopathic hirsutism and in normal subjects.
    Meczekalski B; Slopien R; Warenik-Szymankiewicz A
    Eur J Obstet Gynecol Reprod Biol; 2007 May; 132(1):88-92. PubMed ID: 16979812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disturbances of androgen secretion and metabolism in polycystic ovary syndrome.
    Lobo RA
    Clin Obstet Gynaecol; 1985 Sep; 12(3):633-47. PubMed ID: 2933204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
    Nestler JE; Powers LP; Matt DW; Steingold KA; Plymate SR; Rittmaster RS; Clore JN; Blackard WG
    J Clin Endocrinol Metab; 1991 Jan; 72(1):83-9. PubMed ID: 1898744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum 11 beta-hydroxyandrostenedione as an indicator of the source of excess androgen production in women with polycystic ovaries.
    Polson DW; Reed MJ; Franks S; Scanlon MJ; James VH
    J Clin Endocrinol Metab; 1988 May; 66(5):946-50. PubMed ID: 3129451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen response in polycystic ovarian syndrome to FSH treatment after LHRH agonist suppression.
    Hamori M; Zwirner M; Clédon P; Tinneberg HR
    Int J Fertil; 1992; 37(3):171-5. PubMed ID: 1355764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No changes of peripheral insulin resistance in polycystic ovary syndrome after long-term reduction of endogenous androgens with leuprolide.
    Lasco A; Cucinotta D; Gigante A; Denuzzo G; Pedulla M; Trifiletti A; Frisina N
    Eur J Endocrinol; 1995 Dec; 133(6):718-22. PubMed ID: 8548057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The origin of androgen synthesis in polycystic ovary syndrome.
    Milewicz A; Silber D; Mielecki T
    Obstet Gynecol; 1983 Nov; 62(5):601-4. PubMed ID: 6225965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease.
    DeVane GW; Czekala NM; Judd HL; Yen SS
    Am J Obstet Gynecol; 1975 Feb; 121(4):496-500. PubMed ID: 125040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin resistance in nonobese patients with polycystic ovarian disease.
    Chang RJ; Nakamura RM; Judd HL; Kaplan SA
    J Clin Endocrinol Metab; 1983 Aug; 57(2):356-9. PubMed ID: 6223044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased 5 alpha-reductase activity in idiopathic hirsutism.
    Serafini P; Lobo RA
    Fertil Steril; 1985 Jan; 43(1):74-8. PubMed ID: 3155511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian and adrenal contributions to peripheral androgens in hirsute women.
    Abraham GE; Chakmakjian ZH; Buster JE; Marshall JR
    Obstet Gynecol; 1975 Aug; 46(2):169-73. PubMed ID: 125398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hirsutism and virilism in women.
    Kirschner MA
    Spec Top Endocrinol Metab; 1984; 6():55-93. PubMed ID: 6084314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.